|
1
|
Moll R, Franke WW, Schiller DL, Geiger B
and Krepler R: The catalog of human cytokeratins: patterns of
expression in normal epithelia, tumors and cultured cells. Cell.
31:11–24. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miettinen M: Keratin 20:
immunohistochemical marker for gastrointestinal, urothelial, and
Merkel cell carcinomas. Mod Pathol. 8:384–388. 1995.PubMed/NCBI
|
|
3
|
Maeda T, Kajiyama K, Adachi E, Takenaka K,
Sugimachi K and Tsuneyoshi M: The expression of cytokeratins 7, 19,
and 20 in primary and metastatic carcinomas of the liver. Mod
Pathol. 9:901–909. 1996.PubMed/NCBI
|
|
4
|
Rullier A, Le Bail B, Fawaz R, Blanc JF,
Saric J and Bioulac-Sage P: Cytokeratin 7 and 20 expression in
cholangiocarcinomas varies along the biliary tract but still
differs from that in colorectal carcinoma metastasis. Am J Surg
Pathol. 24:870–876. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shimonishi T, Miyazaki K and Nakanuma Y:
Cytokeratin profile relates to histological subtypes and
intrahepatic location of intrahepatic cholangiocarcinoma and
primary sites of metastatic adenocarcinoma of liver.
Histopathology. 37:55–63. 2000. View Article : Google Scholar
|
|
6
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition.
Springer; New York, NY: 2010
|
|
7
|
Nakanuma Y, Curado MP, Franceschi S, Gores
G, Paradis V, Sripa B, Tsui WMS and Wee A: Intrahepatic
cholangiocarcinoma. WHO Classification Of Tumours Of The Digestive
System. Bosman FT, Carneiro F, Hruban RH and Theise ND: 4th
edition. IARC Press; Lyon: pp. 217–224. 2010
|
|
8
|
Moll R, Lowe A, Laufer J and Franke WW:
Cytokeratin 20 in human carcinomas. A new histodiagnostic marker
detected by monoclonal antibodies. Am J Pathol. 140:427–447.
1992.PubMed/NCBI
|
|
9
|
Zen Y, Fujii T, Itatsu K, et al: Biliary
papillary tumors share pathological features with intraductal
papillary mucinous neoplasm of the pancreas. Hepatology.
44:1333–1343. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakanuma Y, Sasaki M, Ishikawa A, Tsui W,
Chen TC and Huang SF: Biliary papillary neoplasm of the liver.
Histol Histopathol. 17:851–861. 2002.PubMed/NCBI
|
|
11
|
Zen Y, Sasaki M, Fujii T, et al: Different
expression patterns of mucin core proteins and cytokeratins during
intrahepatic cholangiocarcinogenesis from biliary intraepithelial
neoplasia and intraductal papillary neoplasm of the bile duct - an
immunohistochemical study of 110 cases of hepatolithiasis. J
Hepatol. 44:350–358. 2006.
|
|
12
|
Sugimachi K, Taguchi K, Aishima S, et al:
Altered expression of beta-catenin without genetic mutation in
intrahepatic cholangiocarcinoma. Mod Pathol. 14:900–905. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hidaka E, Yanagisawa A, Seki M, Setoguchi
T and Kato Y: Genetic alterations and growth pattern in biliary
duct carcinomas: loss of heterozygosity at chromosome 5q bears a
close relation with polypoid growth. Gut. 48:656–659. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Isa T, Tomita S, Nakachi A, Miyazato, et
al: Analysis of microsatellite instability, K-ras gene mutation and
p53 protein overexpression in intrahepatic cholangiocarcinoma.
Hepatogastroenterology. 49:604–608. 2002.PubMed/NCBI
|
|
15
|
Guedj N, Zhan Q, Perigny M, et al:
Comparative protein expression profiles of hilar and peripheral
hepatic cholangiocarcinomas. J Hepatol. 51:93–101. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jain R, Fischer S, Serra S and Chetty R:
The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of
the pancreas, gastrointestinal tract, and liver. Appl
Immunohistochem Mol Morphol. 18:9–15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
18
|
de Jong MC, Nathan H, Sotiropoulos GC, et
al: Intrahepatic cholangiocarcinoma: an international
multi-institutional analysis of prognostic factors and lymph node
assessment. J Clin Oncol. 29:3140–3145. 2011.PubMed/NCBI
|
|
19
|
Briggs CD, Neal CP, Mann CD, Steward WP,
Manson MM and Berry DP: Prognostic molecular markers in
cholangiocarcinoma: a systematic review. Eur J Cancer. 45:33–47.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Linder S: Cytokeratin markers come of age.
Tumour Biol. 28:189–195. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aishima S, Asayama Y, Taguchi K, et al:
The utility of keratin 903 as a new prognostic marker in
mass-forming-type intrahepatic cholangiocarcinoma. Mod Pathol.
15:1181–1190. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Uenishi T, Yamazaki O, Tanaka H, et al:
Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in
intrahepatic cholangiocarcinoma. Ann Surg Oncol. 15:583–589. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Higashi M, Yonezawa S, Ho JJ, et al:
Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile
duct tumors: its relationship with a new morphological
classification of cholangiocarcinoma. Hepatology. 30:1347–1355.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park SY, Roh SJ, Kim YN, et al: Expression
of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic
impact. Oncol Rep. 22:649–657. 2009.PubMed/NCBI
|
|
25
|
Matsumura N, Yamamoto M, Aruga A, Takasaki
K and Nakano M: Correlation between expression of MUC1 core protein
and outcome after surgery in mass-forming intrahepatic
cholangiocarcinoma. Cancer. 94:1770–1776. 2002. View Article : Google Scholar
|
|
26
|
Hong SM, Cho H, Moskaluk CA, Frierson HF
Jr, Yu E and Ro JY: CDX2 and MUC2 protein expression in
extrahepatic bile duct carcinoma. Am J Clin Pathol. 124:361–370.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tamada S, Goto M, Nomoto M, et al:
Expression of MUC1 and MUC2 mucins in extrahepatic bile duct
carcinomas: its relationship with tumor progression and prognosis.
Pathol Int. 52:713–723. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boonla C, Wongkham S, Sheehan JK, et al:
Prognostic value of serum MUC5AC mucin in patients with
cholangiocarcinoma. Cancer. 98:1438–1443. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aishima S, Kuroda Y, Nishihara Y, et al:
Gastric mucin phenotype defines tumour progression and prognosis of
intrahepatic cholangiocarcinoma: gastric foveolar type is
associated with aggressive tumour behaviour. Histopathology.
49:35–44. 2006. View Article : Google Scholar
|
|
30
|
Thuwajit P, Chawengrattanachot W, Thuwajit
C, Sripa B, Paupairoj A and Chau-In S: Enhanced expression of mucin
6 glycoprotein in cholangiocarcinoma tissue from patients in
Thailand as a prognostic marker for survival. J Gastroenterol
Hepatol. 23:771–778. 2008. View Article : Google Scholar : PubMed/NCBI
|
